UCB (EBR:UCB) UCB Media Room: New biotechnology plant in Belgium

Directive transparence : information réglementée

18/12/2019 18:30
https://u7061146.ct.sendgrid.net/wf/click?upn=3DG62jSYfZdO-2F12d8lSllQBx1W2= 7HkUdGSImvHQ6Hnxeewkzp2Cyp3YauSEmUKxiEcFIepYXu6eaWi0XL1pnaWs963D4Pifl-2FI1K= 6Elr3smEeEBSeUxdwtyDQw5z6zxUUe_-2B-2Ft0TnE1oEbVIWS8vHM8JK8eu8RpJ4re5BwmFRw6= Tr0XlsWOeqQqZTjzwcPKItQR0hTxd9ZQ7rBLYSOuAKeTefElHQ9EZfLoWbvi8z1TsACUgqp5prX= Fo6bi419ovvRVVVOcksB2seqBlym-2FcE-2FN16umLYg5fccZ6EtioODaEv0YepkFqbvJCE-2By= w4GZAAEIn7DexjEOrBuEQ-2BLvsivYAG8cYGZZdzKcKYdsHhlVo6FfT5zvr0QGNqMq-2B9E54G-= 2Bj2-2Fc3GJD1NIyxx-2F0W6yfTozmvA8lGLQSUu5y-2BdxPKhr8mn24fLoTRry-2B3AZZ77gq4= CBdwykMFUump9i9uUBrbNFdHOrj30miCCrVctbYnZL4-3D ** Expanding its portfolio of medicines: UCB to build new biotech manufactu= ring plant in Belgium ------------------------------------------------------------ =C2=B7 Capacity to serve global late-stage development and commercial manuf= acturing of monoclonal antibody drug substance to support new product launc= hes Brussels, Belgium Dec 18, 2019 =E2=80=93 UCB, a global biopharmaceutical co= mpany, today announced it will build an innovative and environmentally sust= ainable multi-product biological manufacturing facility on their site in Br= aine l=E2=80=99Alleud, Wallonia, Belgium. The new biotechnology plant is be= ing constructed to accompany the company=E2=80=99s growth and prepare for t= he launch and long-term supply of future medicines currently in clinical de= velopment. =C2=A0=C2=A0 The new facility, representing an investment of more than 300 million euros= over the coming years, is expected to be operational in 2024. Construction= is due to start in the first quarter of 2020. The biotechnology plant will= be one of the largest and most modern in Belgium.=C2=A0 =E2=80=9CThe shift of our pipeline towards large molecules requires us to r= amp up investment in mammalian technical development, as well as our manufa= cturing capabilities. We are convinced Braine l=E2=80=99Alleud is an ideal = location for the implementation of this large-scale manufacturing facility.= And the presence of our Biotech Sciences Team, Bio-Pilot plant and diverse= research capabilities on the same site will ensure accelerated product lau= nches and supply reliability,=E2=80=9D said Dr. Kirsten Lund-Jurgensen, EVP= and Head of Supply & Technology at UCB.=C2=A0 Construction of the new biomanufacturing plant will also have a positive ef= fect on employment. UCB is expecting to create more than 150 new, high skil= led jobs once the plant becomes fully operational. =C2=A0=C2=A0 About UCB UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company = focused on the discovery and development of innovative medicines and soluti= ons to transform the lives of people living with severe diseases of the imm= une system or of the central nervous system. With more than 7 500 people in= approximately 40 countries, UCB generated revenue of =E2=82=AC 4.6 billion= in 2018. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Tw= itter: @UCB_news For further information =E2=80=93=C2=A0 Corporate Communications Laurent Schots=C2=A0 Media Relations, UCB =C2=A0 T+32.2.559.92.64 =C2=A0Laurent.schots@ucb.com=C2=A0 Investor Relations Antje Witte =C2=A0 =C2=A0 =C2=A0 =C2=A0 =C2=A0 Investor Relations, UCB T +32.2.559.94.14 antje.witte@ucb.com Isabelle Ghellynck, Investor Relations, UCB T+32.2.559.9588, isabelle.ghellynck@ucb.com=C2=A0 Forward looking statements UCB This press release contains forward-looking statements based on current pla= ns, estimates and beliefs of management. All statements, other than stateme= nts of historical fact, are statements that could be deemed forward-looking= statements, including estimates of revenues, operating margins, capital ex= penditures, cash, other financial information, expected legal, political, r= egulatory or clinical results and other such estimates and results. By thei= r nature, such forward-looking statements are not guarantees of future perf= ormance and are subject to risks, uncertainties and assumptions which could= cause actual results to differ materially from those that may be implied b= y such forward-looking statements contained in this press release. Importan= t factors that could result in such differences include: changes in general= economic, business and competitive conditions, the inability to obtain nec= essary regulatory approvals or to obtain them on acceptable terms, costs as= sociated with research and development, changes in the prospects for produc= ts in the pipeline or under development by UCB, effects of future judicial = decisions or governmental investigations, product liability claims, challen= ges to patent protection for products or product candidates, changes in law= s or regulations, exchange rate fluctuations, changes or uncertainties in t= ax laws or the administration of such laws and hiring and retention of its = employees.=C2=A0 Additionally, information contained in this document shall not constitute a= n offer to sell or the solicitation of an offer to buy any securities, nor = shall there be any offer, solicitation or sale of securities in any jurisdi= ction in which such offer, solicitation or sale would be unlawful prior to = the registration or qualification under the securities laws of such jurisdi= ction. UCB is providing this information as of the date of this document an= d expressly disclaims any duty to update any information contained in this = press release, either to confirm the actual results or to report a change i= n its expectations. There is no guarantee that new product candidates in the pipeline will prog= ress to product approval or that new indications for existing products will= be developed and approved. Products or potential products which are the su= bject of partnerships, joint ventures or licensing collaborations may be su= bject to differences between the partners. Also, UCB or others could discov= er safety, side effects or manufacturing problems with its products after t= hey are marketed. Moreover, sales may be impacted by international and domestic trends toward= managed care and health care cost containment and the reimbursement polici= es imposed by third-party payers as well as legislation affecting biopharma= ceutical pricing and reimbursement. GenericFile UCB New Bio Plant Announcement Dec 18 ENG (https://u7061146.ct.sendgrid.net= /wf/click?upn=3DG62jSYfZdO-2F12d8lSllQBx1W27HkUdGSImvHQ6Hnxeewkzp2Cyp3YauSE= mUKxiEcxPplQXA8XOm3UulCZd7Ujso55G-2BJCYCh6Xgvm5RrxWM-3D_-2B-2Ft0TnE1oEbVIWS= 8vHM8JK8eu8RpJ4re5BwmFRw6Tr0XlsWOeqQqZTjzwcPKItQR0hTxd9ZQ7rBLYSOuAKeTefElHQ= 9EZfLoWbvi8z1TsACUgqp5prXFo6bi419ovvRVVVOcksB2seqBlym-2FcE-2FN16umLYg5fccZ6= EtioODaEv0YepkFqbvJCE-2Byw4GZAAEIn7DexjEOrBuEQ-2BLvsivYAAgFheWFdqfyIyGbOHWO= gpQbDENw7YQgcwX3Z2qPQUdmfM6gtJY7P5pQaCqNPcfvvOD-2BKgsl8S7B-2BWNBNYj9ZzWyNeG= AwpdGmxlwTYuqks-2FNOtj-2B5Pd7v5mDq7Uk1i9MrukAqw1-2BaQ0HerKGlkoxRfQ-3D Gener= icFile UCB New Bio Plant Announcement Dec 18 FR (https://u7061146.ct.sendgrid.net/= wf/click?upn=3DG62jSYfZdO-2F12d8lSllQBx1W27HkUdGSImvHQ6Hnxeewkzp2Cyp3YauSEm= UKxiEcEsoPpxPRcM0SVt4WxAgXj9Yirwz13GKv1ITcqtAImrE-3D_-2B-2Ft0TnE1oEbVIWS8vH= M8JK8eu8RpJ4re5BwmFRw6Tr0XlsWOeqQqZTjzwcPKItQR0hTxd9ZQ7rBLYSOuAKeTefElHQ9EZ= fLoWbvi8z1TsACUgqp5prXFo6bi419ovvRVVVOcksB2seqBlym-2FcE-2FN16umLYg5fccZ6Eti= oODaEv0YepkFqbvJCE-2Byw4GZAAEIn7DexjEOrBuEQ-2BLvsivYADoxc-2FPGBZwv31FMmdfOk= qAc-2FLFApIRR6CUNF2wCxeKFjfTmKyOFuCUUqZCIMn5-2BMUXhF-2F5sB8wv8axEa3rR0mukI-= 2Fi59wka-2B048SfHdiGBJUEFv3c2-2BWrc6OrNmzhA9g0t2PAn0ejNDO07c4nmmZK4-3D Gene= ricFile UCB New Bio Plant Announcement Dec 18 NL (https://u7061146.ct.sendgrid.net/= wf/click?upn=3DG62jSYfZdO-2F12d8lSllQBx1W27HkUdGSImvHQ6Hnxeewkzp2Cyp3YauSEm= UKxiEc-2FqOpEJFRfv-2F353bxtgSqRjfueUj4yLEK7ZLc53kta3g-3D_-2B-2Ft0TnE1oEbVIW= S8vHM8JK8eu8RpJ4re5BwmFRw6Tr0XlsWOeqQqZTjzwcPKItQR0hTxd9ZQ7rBLYSOuAKeTefElH= Q9EZfLoWbvi8z1TsACUgqp5prXFo6bi419ovvRVVVOcksB2seqBlym-2FcE-2FN16umLYg5fccZ= 6EtioODaEv0YepkFqbvJCE-2Byw4GZAAEIn7DexjEOrBuEQ-2BLvsivYAELy7PzCwV46CS9edf1= wIlXOdSUGXVCqEyoSzl3aH4B3mhCuYIZOwg2IATLF2UUoHv55EkXDbXa-2BubE0A6WbdGRkWvaq= K6MMgqb3ufC-2F1H00lYfrhQtUG4HqpcWk8TF6X0GPKD2Hs1vAWDejezIXhpw-3D Image Inflexio 2mb (https://u7061146.ct.sendgrid.net/wf/click?upn=3DG62jSYfZdO-2F= 12d8lSllQBx1W27HkUdGSImvHQ6Hnxeewkzp2Cyp3YauSEmUKxiEcj-2FZ9PdJG6YS8DpWoYHuo= FRuqLPn-2Bjo5d4-2FVllucbcaY-3D_-2B-2Ft0TnE1oEbVIWS8vHM8JK8eu8RpJ4re5BwmFRw6= Tr0XlsWOeqQqZTjzwcPKItQR0hTxd9ZQ7rBLYSOuAKeTefElHQ9EZfLoWbvi8z1TsACUgqp5prX= Fo6bi419ovvRVVVOcksB2seqBlym-2FcE-2FN16umLYg5fccZ6EtioODaEv0YepkFqbvJCE-2By= w4GZAAEIn7DexjEOrBuEQ-2BLvsivYABnmKvbg4sf9QHRFoz9p33fS57mVn0lghYU-2Fnm-2B5Q= UrJjTK-2BlOgpStPxjCIuym9kXK-2Fcax1U6zfFiFenpsfuf48SxiR3Y-2BgzrhByuCyTcN6WBW= HZ95Op97lLSpmZ-2FKKy5T5MkH2l8SXimcBXlEzvEww-3D=0D =0D ______________________=0D If you would rather not receive future communications from UCB SA, please g= o to https://u7061146.ct.sendgrid.net/wf/click?upn=3DG62jSYfZdO-2F12d8lSllQ= Bz2p53T0v-2BoEIvbo6vDi8C-2BOyFzyb6obo-2BzKSgNKq4mrTKZv-2FNwuhn1s6s08kBBp8QU= KA2P-2B28yTcjvH0qBeKW8AFA1XN-2BQmRYAM1-2BTYp5tS0FH9LIYGCjdw2uPm9ffJ00-2BwWC= nxf8-2BYzCeSdcb-2Bcio-3D_-2B-2Ft0TnE1oEbVIWS8vHM8JK8eu8RpJ4re5BwmFRw6Tr0Xls= WOeqQqZTjzwcPKItQR0hTxd9ZQ7rBLYSOuAKeTefElHQ9EZfLoWbvi8z1TsACUgqp5prXFo6bi4= 19ovvRVVVOcksB2seqBlym-2FcE-2FN16umLYg5fccZ6EtioODaEv0YepkFqbvJCE-2Byw4GZAA= EIn7DexjEOrBuEQ-2BLvsivYANPwO1kmbGguJf-2Fcxjo8uu67fcV0bjT3B1KUepdd-2Bq-2F6l= aw5vuJvGr-2BR8y2cra8rGc47XxgPOvt5IJOik9Bf6oOuX8URq7o81Hdaha6yOB7lVrmh6rpiQi= jgSgzWo-2FSfAM-2BLhSX4Ra7sXy288uswO2E-3D=0D UCB SA, All=C3=A9e de la Recherche, 60 ., Brussels, . B - 1070 Belgium=

24/02/2020 20:00
20/02/2020 07:00
14/02/2020 20:01
10/02/2020 20:00
31/01/2020 20:01
28/01/2020 07:01
27/01/2020 20:00
20/01/2020 20:10
20/01/2020 20:05
20/01/2020 20:01